This Analyst Believes Seagen Is Evaluating Strategic Alternatives
This Analyst Believes Seagen Is Evaluating Strategic Alternatives
这位分析师认为，西根正在评估战略选择
- Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price.
- Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company.
- The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder.
- Related: Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
- The biggest counterpoint to a potential buyout of Seagen is the cluster of potential patent expiry around 2030. The analysts estimate peak sales of ~$6.7 billion in 2030 but are likely below internal risk-modeled assessments.
- "Overall, the expected growth of the existing Seagen commercial portfolio, significant optionality of label expansion for key programs such as PADCEV, and general increased interest in the ADC modality post-DestinyBreast-04, will likely support Seagen as a high-interest candidate," notes Raymond James.
- Price Action: SGEN shares are down 0.15% at $178.40 during the market session on the last check Wednesday.
- Raymond James initiated coverage on Seagen Inc (NASDAQ:SGEN) at Outperform with a $220 target price.
- Citing the recent departure of the long-time Seagen CEO, Raymond James thinks that the Board of Directors is likely evaluating strategic alternatives for the company.
- The relationship with Merck & Company, Inc. (NYSE:MRK) has been long-standing. With Keytruda losing its patent and limited existing antibody-drug conjugate exposure, Merck could be seen as a viable bidder.
- Related: Merck/Seagen Potential Deal Talks Pick Up Speed: WSJ
- The biggest counterpoint to a potential buyout of Seagen is the cluster of potential patent expiry around 2030. The analysts estimate peak sales of ~$6.7 billion in 2030 but are likely below internal risk-modeled assessments.
- "Overall, the expected growth of the existing Seagen commercial portfolio, significant optionality of label expansion for key programs such as PADCEV, and general increased interest in the ADC modality post-DestinyBreast-04, will likely support Seagen as a high-interest candidate," notes Raymond James.
- Price Action: SGEN shares are down 0.15% at $178.40 during the market session on the last check Wednesday.
- 雷蒙德·詹姆斯在以下日期开始覆盖SeaGen公司(纳斯达克：SGEN)强于大盘，目标价为220美元。
- 雷蒙德·詹姆斯认为，董事会可能正在评估公司的战略选择，理由是长期担任Seagen首席执行官的雷蒙德·詹姆斯最近离职了。
- 与中国的关系默克公司(纽约证券交易所代码：MRK)由来已久。随着Keytruda失去专利，并限制现有的抗体-药物结合物暴露，默克可以被视为一个可行的竞购者。
- 相关：默克/Seagen潜在交易谈判提速：《华尔街日报》
- 对Seagen的潜在收购最大的对立面是2030年左右到期的一系列潜在专利。分析师估计，2030年的峰值销售额约为67亿美元，但可能低于内部风险模型评估。
- 雷蒙德·詹姆斯指出：“总体而言，现有Seagen商业产品组合的预期增长、PADCEV等关键项目标签扩展的显著可选性，以及DestinyBreast-04之后人们对ADC模式的普遍兴趣增加，可能会支持Seagen成为一个高兴趣的候选者。”
- 价格行动：截至周三尾盘，Sgen股价下跌0.15%，至178.40美元。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
风险及免责提示
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
知道了
抢沙发
0 0 0
赞大爱笑哭社会社会Emm心碎怒
轻触选择心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧
点击这里分享给好友
暂无评论，快来抢沙发吧！